Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06066541 · ClinicalTrials.gov registry record · NA

Social Norms, Messengers, and Processing Fluency to Increase Hypertension Medication Adherence

A NA study of Hypertension and Medication Adherence, sponsored by Brigham and Women's Hospital.

Completed
Registry status
NA
Development phase
65,177
Enrollment target
1
Study location

NCT06066541 is a NA study of Hypertension and Medication Adherence that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 65,177 participants, above the 3,369-participant average among 470 other Hypertension trials with a reported enrollment target (1835% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06066541, a NA study of Hypertension and Medication Adherence, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
NA
Development phase
65,177 participants
Enrollment target
1
Study location

Study Summary

Medicare Advantage beneficiaries ages 65-79 and insured by Humana with at least two unique fills of hypertension medication within the 2023 calendar year and adherence level between 60 and 85% will be identified using Humana Medicare Advantage claims data. Individuals meeting these inclusion criteria will be included and, with an institutional review board approved waiver of informed consent, will be randomized to one of 6 mailed messages or control (no message). The messages will be sent by Humana and use different behavioral techniques (social norms, messenger effects, and/or processing fluency) providing their medication refill score. Humana will send a second message within 60 days of the first message noting any changes in the refill score. The primary outcome will be the average end-of-year adherence in each arm. A secondary outcome will be the proportion of study participants with end-of-year adherence greater than or equal to 80%. The study team's hypothesis is that messages using dynamic social norms, messenger effects, and processing fluency in combination will more effectively increase average end-of-year adherence level compared to usual care. Humana will conduct all study participant outreach and data analyses, which will be performed using routinely collected insurance claims data. Regulatory oversight is conducted using Humana's centralized institutional review board (IRB) of record. The work completed by Humana study staff is funded by Humana, Inc. Dr. Choudhry and his colleagues (including subaward recipients ideas42 and Tuck School of Business at Dartmouth) will provide technical and subject matter expertise related to study research design and implementation, protocol design, statistical analysis, publication (abstract, poster, manuscript) preparation and/or review, and assistance throughout the peer review process including revisions and additional analyses if necessary for this project. The work completed by study staff at Brigham and Women's

Interventions

  • BEHAVIORAL Scorecard
  • BEHAVIORAL Social norms
  • BEHAVIORAL Messenger effects
  • BEHAVIORAL Processing fluency

Study Locations (1)

Kentucky

  • Humana, Inc. - Louisville

Trial Details

FieldValue
Enrollment Target 65,177 participants
Start Date 2023-08-18
Est. Completion 2023-12-31
Phase NA

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT06066541

The ClinicalTrials.gov registry entry for NCT06066541 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 65,177 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,369-participant average among 470 other Hypertension trials with a reported enrollment target (1835% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 4 interventions - of which Scorecard is the first listed.

NCT06066541 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT06066541 about?

NCT06066541 is a clinical study titled "Social Norms, Messengers, and Processing Fluency to Increase Hypertension Medication Adherence". Medicare Advantage beneficiaries ages 65-79 and insured by Humana with at least two unique fills of hypertension medication within the 2023 calendar year and adherence level between 60 and 85% will be identified using Humana Medicare Advantage claims data. Individuals meeting these inclusion criteri...

What is the current status of trial NCT06066541?

This trial is currently completed. It is a NA study. The enrollment target is 65,177 participants. The study started on 2023-08-18. Estimated completion is 2023-12-31.

What conditions does trial NCT06066541 study?

This clinical trial studies the following conditions: Hypertension, Medication Adherence.

What interventions are being tested in trial NCT06066541?

The interventions under investigation include: Scorecard (BEHAVIORAL), Social norms (BEHAVIORAL), Messenger effects (BEHAVIORAL), Processing fluency (BEHAVIORAL).

Who is sponsoring clinical trial NCT06066541?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06066541 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.